Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
   
Ask the Experts About

HIV Drug ResistanceHIV Drug Resistance
           
Rollover images to visit our other forums!
  
  • Email Email
  • Glossary Glossary


presista
Oct 9, 2006

what are the mutations that presista is resistant to?

Response from Dr. Sherer

I am a little wary of answering this question out of context, so I will answer it and provide some background as well. I will also urge you to talk to your doctor about your question and this answer, as a person in whom Prezista (darunavir) is being considered or given is likely to have a complicated treatment history and multiple resistance mutations. A single answer in isolation is not a good idea in such a case.

Prezista (darunavir) is the newest protease inhibitor. It is co-administered with ritonavir twice daily, and it has excellent activity against viruses that are resistant to most current PIs, including fosamprenavir, lopinavir, and atizanavir. In clinical trials of patients with extensive treatment histories and multiple PI mutations, it was able to achieve a viral load below detection in 30-65% of patients, depending on their level of resistance, whether or not one or more active NRTIs was in their regimen, and whether or not enfurvitide (T-20) was also added to the regimen. It is used in settings similar to tipranavir, which is also a new PI with activity against multi-PI resistant virus. As such, it has achieved much attention. It has appeared to be well tolerated, and has side effects and toxicities similar to other boosted PIs. It is NOT a "super" protease inhibitor, and resistance has been demonstrated to occur, which brings me to the answer to your question.

In one study of a panel of 9,968 isolates, >50% have >10-fold reduced susceptibility to darunavir with 3 or more of the following key mutations: V11I, V32I, L33F, I47V, I50V, I54L, I54M, G73S, L76V, I84V and L89V

To date, the phenotype cut-offs that have been proposed are for some reduction in susceptibility at > 10 fold, and near complete loss of susceptibility at > 40-69 fold, but the clinical correlations with these cut-offs have not been established.

I doubt that these numbers are of much value to you. I encourage you to ask your question of your doctor, and to share these observations with him or her.


Previous
Have I become Drug resistant?
Next
Kaletra & Truvada & Sulfamethazole

  
  • Email Email
  • Glossary Glossary


 
 
Advertisement




Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement